Table 3.

Brief Negative Symptom Scale (BNSS) scores in clinical and control groups pre- and during-pandemic

	Study 1 Study 2
	SZ		CN	CHR		CN
	Pre	During	During	Pre	During	During
MAP	1.23 (1.17)	2.11 (1.54)	0.86 (1.01)	1.28 (0.54)	1.44 (1.05)	0.75 (0.86)
EXP	0.82 (1.08)	1.57 (1.41)	0.64 (1.44)	0.47 (0.79)	0.6 (0.91)	0.47 (0.72)
Anhedonia	1.23 (1.51)	2.12 (1.72)	0.91 (1.16)	1.43 (0.9)	1.48 (1.29)	0.74 (0.91)
Asociality	1.02 (1.29)	1.72 (1.56)	0.87 (1.05)	1.02 (0.9)	1.17 (1.04)	0.72 (0.79)
Avolition	1.45 (1.28)	2.5 (1.8)	0.78 (1.18)	1.31 (0.97)	1.67 (1.26)	0.79 (1.35)
Blunted affect	1.19 (1.44)	1.67 (1.31)	0.49 (1.01)	0.65 (1.08)	0.71 (1.12)	0.47 (0.75)
Alogia	0.27 (0.81)	1.47 (1.68)	0.58 (1.46)	0.19 (0.43)	0.45 (0.86)	0.5 (0.81)

All values are mean with SD in parentheses

BNSS Brief Negative Symptom Scale, CHR clinical high-risk, CN control, SZ schizophrenia, MAP motivation and pleasure, EXP diminished expression, Pre pre-pandemic, During during pandemic, Note CN were only evaluated during the pandemic in both studies